| Document |
Document Title |
|
WO/2024/085480A1 |
The present invention relates to: lactic acid bacteria extracellular membrane protein PrsA having a cell surface display anchor motif function; and a vector system for cell surface display of a target protein, the system comprising a seq...
|
|
WO/2024/082178A1 |
Provided is a chimeric antigen receptor, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain targets CD19, and the second antigen-binding domain targets CD22. Also provi...
|
|
WO/2024/085246A1 |
The purpose of the present invention is to provide: a biomarker which can determine the presence or absence of the affection of dementia with high sensitivity and specificity by means of a simple operation; and a method, a kit, and a dev...
|
|
WO/2024/084124A1 |
The present invention relates to a Cas9 endonuclease protein comprising an amino acid sequence according to SEQ ID NO:1, to the nucleotide sequence encoding said protein, to the expression vector comprising said sequence, to the cell com...
|
|
WO/2024/086747A1 |
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistributi...
|
|
WO/2024/084807A1 |
Provided is a method for assaying fibroblast growth factor 18 (FGF18), whereby FGF18 can be detected/assayed with specificity. In the present invention, fibroblast growth factor 18 (FGF18) in a sample is assayed using a first antibody ...
|
|
WO/2024/083135A1 |
The disclosure provides IscB polypeptides for various applications, e.g., double-strand cleavage, base editing, prime editing.
|
|
WO/2024/086845A2 |
Described herein are variants of CasPhi2 nucleases with enhanced editing capabilities and methods of use thereof.
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/084519A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/082624A1 |
Provided are a primer having stem-loop structures and the use thereof. The primer sequentially comprises, from the 5' end to the 3' end, primer region 1, inosines, stem-loop structure 1, primer region 2, stem-loop structure 2 and primer ...
|
|
WO/2024/082795A1 |
The present invention relates to a protein and a vaccine against infections of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, which belong to the field of medicines. In order to solve the problem of lack of effective prevent...
|
|
WO/2024/086549A1 |
This invention relates chimeric alphavirus genomes, alphavirus particles and compositions comprising the same, and their use in methods of directed evolution, such as methods of modify a heterologous nucleic acid, evolving a heterologous...
|
|
WO/2024/084007A1 |
The present invention relates to inhibitors, pharmaceutical compositions and methods for inhibiting the expression of Fos-related antigen-1 (Fra-1) or Fos-related antigen-2 (Fra-2) in fibrogenic tissue cells for use in the treatment or p...
|
|
WO/2024/084054A1 |
The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, each segment being operably linked t...
|
|
WO/2024/084025A1 |
The invention pertains to a method for producing a plant cell comprising a modified RNA molecule, comprising the steps of i) providing the plant cell; and ii) introducing the modified RNA molecule into the plant cell. The modified RNA mo...
|
|
WO/2024/086512A1 |
Methods and systems for analyzing lipid nanoparticles using size exclusion chromatograph coupled with multi angle light scattering are disclosed.
|
|
WO/2024/082005A1 |
The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising the...
|
|
WO/2024/085132A1 |
This biological substance treatment method involves preparing a flow cell 1 comprising: a chamber array device 11 provided with a plurality of chambers 14 in which one of the chambers is 1 nanoliter or less; and a cover body 21 defining ...
|
|
WO/2024/082945A1 |
A multi-omics library construction method, a detection method, and a related kit. The multi-omics library construction method comprises: placing a slice sample on a chip having a PolyA capture function for protein capture and mRNA captur...
|
|
WO/2024/086628A2 |
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with increased transduction enrichment in the brain and, in some cases, reduced transduction in the liver. The rAAV compositions describe...
|
|
WO/2024/084082A1 |
The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of...
|
|
WO/2024/086846A1 |
Compositions comprising one or more peptide antigens for immunizing an avian animal against C. hepaticus, or a vector for expressing the one or more peptide antigens in vivo are disclosed. Methods of immunizing an avian animal against C....
|
|
WO/2024/086400A1 |
This disclosure relates to a modified oncolytic herpes simplex virus (oHSV) comprising an expression cassette encoding a histidine-rich glycoprotein (HRG), and uses thereof. One promising avenue for the treatment of cancer is oncolytic v...
|
|
WO/2024/086669A2 |
The disclosure relates generally to gene editing systems comprising reverse transcriptases and fusion proteins of reverse transcriptases with nickases or nucleases, methods of making such reverse transcriptases and fusion proteins, and m...
|
|
WO/2024/086609A2 |
The present disclosure provides for nucleic acids encoding for a soluble PD-1 variant and IL-12. Further provided herein are nucleic acids encoding for a chemokine receptor. Additionally described herein are oncolytic viruses comprising ...
|
|
WO/2024/083095A1 |
A circular RNA, a vector, and a use of the vector. The circular RNA comprises an antisense sequence which may specifically bind to a target RNA by means of complementary base pairing, and a 5' connecting sequence and a 3' connecting sequ...
|
|
WO/2024/084048A1 |
The invention relates to a heteroduplex RNA editing oligonucleotide complex (HEON) comprising a first nucleic acid strand annealed to a second nucleic acid strand, for use in the targeted deamination of a target adenosine present in a ta...
|
|
WO/2024/086614A2 |
The present invention relates to compositions for effective delivery of an agent to a target cell while minimizing off-target expression of the therapeutic agent by administering therapeutic agents that have been modified with an inhibit...
|
|
WO/2024/083985A1 |
The present invention relates to novel peptides (cPEPs & altPEPs), to a method for the preparation thereof, and to the use thereof for modulating the accumulation of specific proteins.
|
|
WO/2024/084075A1 |
The present invention relates to the combination of a nucleic acid encoding a short isoform of rod- derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic...
|
|
WO/2024/082262A1 |
Provided are a splicing system for controlling virus replication in response to a hypoxic environment, and a use thereof. The system comprises, mutually separated or fused to one another, a gene encoding an hypoxia sensing unit and a gen...
|
|
WO/2024/084462A1 |
The present disclosure provides complexes and uses thereof, wherein the complex comprises a first cationic polymer, a second cationic polymer, and a monomeric RNA molecule, wherein the first cationic polymer comprises greater than 250 re...
|
|
WO/2024/084398A2 |
The present disclosure relates generally to polynucleotides, vectors, and cells for producing alpha 2 macroglobulin (A2M), methods of making A2M, and compositions comprising A2M. The present disclosure relates generally to polynucleotide...
|
|
WO/2024/083097A1 |
Disclosed in the present invention is an IL-2 mutant, having at least one of the following mutations on an amino acid sequence of IL-2: 1) an insertion of at least one amino acid residue having a smaller side chain between positions T10 ...
|
|
WO/2024/085212A1 |
Biomarkers for human ALT1 and ALT2 and mouse ALT1 and ALT2, the biomarkers including a peptide for measuring human ALT1, a peptide for measuring human ALT2, a peptide for measuring mouse ALT1 and a peptide for measuring mouse ALT2; and a...
|
|
WO/2024/083185A1 |
The application relates to an isolated monoclonal antibody that specifically binds FGFR2B, or an antigen binding portion thereof. The application also relates to a nucleic acid molecule encoding the antibody or antigen binding portion th...
|
|
WO/2024/086792A2 |
Methods to improve homing and engraftment of hematopoietic stem cells, particularly cord blood CD34+ cells, for use in hematopoietic cell transplantation through the regulation of expression of YTHDF2 or FTO in CD34+ cells. The methods i...
|
|
WO/2024/085686A1 |
The present invention relates to: a recombinant protein comprising a foot-and-mouth disease virus (FMDV) virus-like particle (VLP) and the fragment crystallizable (Fc) region of a porcine-derived immunoglobulin linked to the surface of t...
|
|
WO/2024/082056A1 |
Described herein are antibody constructs that bind human NaPi2b (or SLC34A2) and antibody-drug conjugates (ADCs) comprising an anti-NaPi2b antibody construct conjugated to a drug, such as a cytotoxin or an immune modulator, and their use...
|
|
WO/2024/084518A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a, 100b) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop str...
|
|
WO/2024/085280A1 |
The present invention relates to a novel kynureninase and a use thereof for cancer treatment. The novel kynureninase demonstrates similar or higher catalytic activity and thermal stability compared to already known kynureninases, and is ...
|
|
WO/2024/084852A1 |
The present invention relates to a nucleic acid molecule having a nucleotide sequence that encodes a chimeric antigen receptor (CAR). The present invention relates to a vector containing said nucleic acid molecule. The present invention ...
|
|
WO/2024/086756A1 |
A method of treating, ameliorating, or preventing a condition characterized by one or both of reduced renal function and renal fibrosis is described, which includes interfering with one or both of an expression and an activity of a cadhe...
|
|
WO/2024/084197A1 |
The invention relates to methods for reducing the level of xenobiotic in an environment by contacting the environment with a composition comprising one or more bacterial strains. The invention also relates to bacterial strains for use in...
|
|
WO/2024/083986A1 |
The present invention relates to new peptides (cPEPs), a method for their preparation, and their use for modulating the accumulation of specific proteins.
|
|
WO/2024/086595A2 |
Systems and methods to simplify ex vivo gene therapy are described. The systems and methods provide ex vivo manufacturing of cells using target-cell enriching magnetic beads, vector-magnetic bead complexes, and a magnetic field. The pres...
|
|
WO/2024/086591A2 |
Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.
|
|
WO/2024/083958A1 |
The present invention relates to chimeric polypeptides comprising a scaffold polypeptide and one or more exogenous polypeptides, wherein the scaffold polypeptide comprises a backbone protein 2a (BP-2a) Domain 3 (D3) polypeptide in which ...
|
|
WO/2024/086661A2 |
The disclosure relates generally to gene editing systems comprising reverse transcriptases and fusion proteins of reverse transcriptases with nickases or nucleases, methods of making such reverse transcriptases and fusion proteins, and m...
|
